如咨询分子生物学试剂请点击www.sparkjade.com
请致电
400-694-7688
或联系
在线客服
| 货号 | 产品名 | 中文名称 | 产品描述 |
|---|---|---|---|
| SJ-BP0086 | Terlipressin | 特利加压素 | Terlipressin 是一种具有管活性的加压素类似物，也是一种高度选择性的加压素 V1 受体激动剂，可减少内脏血流量和门脉压力并控制急性静脉曲张破裂出血。Terlipressin 具有抗炎和抗氧化作用，可用于肝肾综合征和耐去甲肾上腺素的败血性休克的研究。 |
| SJ-MX3786 | Lixivaptan | 利希普坦 | Lixivaptan (formerly known as VPA-985, WAY-VPA 985) is a novel, potent, selective and orally bioactive non-peptide antagonist of vasopressin receptor V2 with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively. Lixivaptan works by reducing the action of the hormone vasopressin that blocks fluid excretion. Lixivaptan acts by blocking vasopressin, an anti-diuretic hormone that causes the kidneys to retain water. When the body needs to remain hydrated under certain conditions, vasopressin can have protective effects. |
| SJ-MX3811 | Balovaptan | Balovaptan is a potent and selective vasopressin-1 receptor antagonist. | |
| SJ-MX2607 | Felypressin | 苯赖加压素 | Felypressin (PLV-2) is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. |
| SJ-BP0063 | Desmopressin Acetate | Desmopressin acetate是抗利尿激素精氨酸血管加压素的合成类似物。Desmopressin acetate的抗利尿特性去氨加压素通过限制尿中排出的水量发挥作用，使其可用于多尿症,包括原发性夜间遗尿症、夜尿症和尿崩症。 | |
| SJ-MX2149 | Conivaptan hydrochloride | 盐酸考尼伐坦 | Conivaptan hydrochloride 是一种非肽段类的 vasopressin receptor 拮抗剂，能够抑制大鼠肝脏的 V1A 受体和肾脏的 V2 受体，Ki 值分别为 0.48 和 3.04 nM。 |
| SJ-MX4711 | L-371,257 | L-371,257 是一种口服生物有效的，不能透过血脑屏障的，竞争性的，选择性催产素受体拮抗剂 (pA2=8.4)，对催产素受体 (Ki=19 nM) 和血管加压素 V1a 受体 (vasopressin V1a receptor，Ki=3.7 nM) 具有高亲和力。 | |
| SJ-BP0052 | Atosiban | 阿托西班 | Atosiban is a novel and potent oxytocin and vasopressin antagonist. |
| SJ-BP0187 | Argipressin | 精氨加压素 | Argpressin Acetate is a novel and potent nonapeptide. |
| SJ-MX2795 | Mozavaptan | 莫扎伐普坦 | Mozavaptan (formerly known as OPC-31260; OPC-31260l; OPC31260; OPC31260l) is an orally bioactive, selective and competitive vasopressin receptor antagonist for both V1 and V2 receptors with anti-hypernatremic activity. It inhibits vasopressin V1 and V2 receptors with IC50s of 1.2 μM and 14 nM, respectively. Mozavaptan was developed and marketed by Otsuka Pharm in Japan. Mozavaptan was approved in October 2006 in Japan for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors. |
| SJ-MX4535 | Tolvaptan | 托伐普坦 | Tolvaptan is a highly potent, oral and selective antagonist of vasopressin V2 receptor. |
| SJ-BP0052A | Atosiban acetate | 醋酸阿托西班 | |
| SJ-MX4850 | Fedovapagon |
扫码关注公众号
